Investigation of mutations and expression of the FHIT gene in Turkish patients with brain metastases derived from non-small cell lung cancer

Tumori

Volumn 93, Issue 6, 2007, Pages 604-607

  Bekar, Ahmet ^a   Çeçener, Gülşah ^a   Tunca, Berrin ^a   Guler, Gulnur ^b   Egeli, Unal ^a   Tolunay, Şahsine ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Brain metastases; FHIT gene; Immunohistochemistry; NSCLC; Point mutations

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER PATIENT; CLINICAL ARTICLE; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; POINT MUTATION; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; TURKEY (REPUBLIC);

EID: 38549087385     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160709300615     Document Type: Article

References (26)

1. Fidler IJ: Critical factors in the biology of human cancer metastases: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res, 50: 6130-6138, 1990.
2. Wen PY, Loeffler JS: Management of brain metastases. Oncology (Williston Park), 13: 941-54, 1999.
3. Turkish Ministry of Health. Republic of Turkey Health Statistics. Turkish Ministry of Health. 2000. Available at:http/:www.saglik.gov.tr/istatistikler. Accessed May, 2006.
4. Sozzi G, Veronese M, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K, Croce CM: The FHIT gene At 3p14.2 is abnormal in lung cancer. Cell, 85: 17-26, 1996.
5. Fong KM, Biesterveld EJ, Virmania A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, Minna JD: FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer related FHIT cDNA splicing aberrations. Cancer Res, 57: 2256-2267, 1997.
6. Yanagisawa K, Kondo M, Osada H, Uchida K, Takagi K, Masuda A, Takahashi T, Takahashi T: Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines. Cancer Res, 56: 5579-5582, 1996.
7. Huebner K, Croce CM: Cancer and FRA3B/FHIT fragile locus: it's a HIT. Br J Cancer, 88: 1501-1505, 2003.
8. Frank S, Muller J, Plaschke J, Hahn M, Hampl J, Hampl M, Pistorius S, Schackert G, Schackert HK. The putative tumor suppressor gene FHIT at 3p14.2 is rarely affected by loss of heterozygosity in primary human brain tumors. Cancer Res, 57: 2638-2641, 1997.
9. Kannan K, Krishnamurthy J, Feng J, Nakajima T, Tsuchida N, Shanmugam G. Mutation profile of the p53, FHIT, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas. Int J Oncol, 17: 1031-1035, 2000.
10. Ohta M, Inove H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell, 84: 587-597, 1996.
11. Yoshino K, Enomoto T, Nakamura T, Nakashima R, Wada H, Saitoh J, Noda K, Murata Y: Aberrant FHIT transcripts in squamous cell carcinoma of the uterine cervix. Int J Cancer, 76: 176-181, 1998.
12. Gemma A, Hagiwarn K, Ke Y, Burke LM, Khan MA, Nagashima M, Bennett WP, Harris CC: FHIT mutations in human primary gastric cancer. Cancer Res, 57: 1435-1437, 1997.
13. Tunca B, Bekar A, Cecener G, Egeli U, Vatan O, Tolunay S, Kocaeli H, Aksoy K: Impact of novel PTEN mutations in Turkish patients with glioblastoma multiforme. J Neurooncol, 82: 263-269, 2006.
14. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, Hauck WW, McCue P, Huebner K. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer, 100: 1605-1614, 2004.
15. Malmer B,Feychting M, Lonn S, Ahlbom A, Henriksson R. p53 Genotypes and risk of glioma and meningioma. Cancer Epidemiol Biomarkers Prev, 14: 2220-2223, 2005.
16. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Nakamura H, Kochi M, Kuratsu J, Saya H, Ushio Y: Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme. J Neurosurg, 96: 815-822, 2002.
17. Patchell RA: The management of brain metastases. Cancer Treat Rev, 29: 533-540, 2003.
18. Wen PY, Loeffler JS: Brain metastases. Curr Treat Options Oncol, 1: 447-458, 2000.
19. Huebner K, Croce C: FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer, 1: 214-221, 2001.
20. Mori M, Mimori K, Shiraishi T, Alder H, Inoue H, Tanaka Y: Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res, 67: 1177-1182, 2000.
21. Kitamura A, Yashima K, Okamoto E, Andachi H, Hosoda A, Kishimoto Y, Shiota G, Ito H, Kaibara N, Kawasaki H: Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis. Oncology, 61: 205-211, 2001.
22. Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, Shah KV, Jones RW, Bosch FX, Munoz N, Cho KR: Loss of Fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res, 6: 3505-3510, 2000.
23. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S: Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res, 58: 5032-5037, 1998.
24. Kim HL, Vander Griend DJ, Yang X, Benson DA, Dubauskas Z, Yoshida BA, Chekmareva MA, Ichikawa Y, Sokoloff MH, Zhan P, Karrison T, Lin A, Stadler WM, Ichikawa T, Rubin MA, Rinker-Schaeffer CW: Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res, 61: 2833-2837, 2001.
25. Miyazaki T, Kato H, Shitara Y, Yoshikawa M, Tajima K, Masuda N, Shouji H, Tsukada K, Nakajima T, Kuwano H: Mutation and expression of the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma. Cancer, 89: 955-962, 2000.
26. Cropp CS, Lidereau R, Leone A, Liscia D, Cappa AP, Campbell G, Barker E, Le Doussal V, Steeg PS, Callahan R: NME1 protein expression and loss of heterozygosity mutations in primary human breast tumors. J Natl Cancer Inst, 86: 1167-1169, 1994.